Skip to main content

Table 3 Comparison between patients with PSA (< 1 ng/ml) and PSA (≥ 1 ng/ml)

From: Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy

Variable

Patient with PSA (< 1 ng/ml)

Patient with PSA (≥ 1 ng/ml)

P

Patients (n)

20

30

> 0.05

Age (year) (mean ± SD, range)

70.25 ± 8.17 (52–87)

70.06 ± 10.91 (52–89)

> 0.05

Pre-therapeutic PSA (ng/ml) (median, range)

26 (8–42)

82.50 (22–1201)

> 0.05

Gleason score (median, range)

7 (6–9)

8 (6–9)

> 0.05

Cores involved (mean ± SD, range)

5.19 ± 3.78 (1–12)

5.50 ± 2.75 (1–11)

> 0.05

Percentage of cores involved (mean ± SD, range)

56.88 ± 31.2 (4–100)

72.58 ± 23.4 (12.5–100)

> 0.05

PSA at last follow-up (ng/ml) (median, range)

0.12 (0.02–0.90)

4.64 (1.02–85)

> 0.05

Nadir PSA (ng/ml) (median, range)

0.08 (range 02–0.9)

2.75 (range 1.05–50)

> 0.05

Time to nadir PSA (months) (mean ± SD, range)

3.50 ± 1.42 (2–7)

4.03 ± 1.69 (1–7)

> 0.05

Bone metastasis (n, %)

17 (85%)

24 (80%)

> 0.05

Organ metastasis (n, %)

1 (0.05)

2 (6.66%)

0.04

Lymph node metastasis (n, %)

2 (10%)

4 (13.33%)

0.04

Follow-up (month) (mean ± SD, range)

13.81 + 9.07 (5–28)

13.17 + 6.57 (2–30)

> 0.05

  1. PSA prostate specific antigen, N number of patients, SD standard deviation